Journal Watch - 2015

« Back to Most Recent

  1. Gene therapy via nanoparticles reduces peritoneal fibrosis in mice

    Gene therapies may reduce peritoneal fibrosis—a leading cause of PD failure. Delivering transforming growth factor using nanoparticles worked in a mouse study.

    Read the abstract » | (added 05/09/2015)

    Tags:

  2. Dosage of Tamiflu® for people on PD

    A new study finds that a single, 75mg dose of oseltamivir may be enough for people on PD who don’t have residual kidney function. The more residual function people had, the more efficiently the drug was removed—so more was needed for an optimal response.

    Read the abstract » | (added 05/09/2015)

    Tags:

  3. Glucose challenge test (GCT) detects glucose metabolism disorders in PD

    When glucose-based PD fluid is used, it can be a challenge to see if there are blood sugar issues. In 20 people on PD who did not have a history of diabetes, an initial GCT detected impaired glucose tolerance in eleven and diabetes mellitus in four. About 2 years later, twelve patients had glucose metabolism disorders—but none had diabetes.

    Read the abstract » | (added 05/09/2015)

    Tags:

  4. New index more accurate than Kt/V for PD “adequacy”

    It’s no secret that we at Home Dialysis Central are not fans of Kt/V for HD (or the concept of “adequacy”). A new European study suggests that Kt/V is not useful for PD, either (because it does not account for protein intake), and has tested a substitute index that works better.

    Read the abstract » | (added 05/09/2015)

    Tags: Home Dialysis

  5. Ultrasound can measure peritoneal wall thickness in children

    Fibrosis of the peritoneum can cause PD failure. But, peritoneal wall thickness can be measured with a painless ultrasound. The results can assess whether the peritoneum is changing over time.

    Read the abstract » | (added 05/09/2015)

    Tags:

  6. Maximum ultrafiltration rate as a measure of optimal HD

    Dialysis removes both wastes and water. Yet, while we have measures for waste removal, we have no marker for water—even though, in the short run, it is more important for patient health and well-being. Dr. Agar proposes a maximum ultrafiltration rate.

    Read the abstract » | (added 04/10/2015)

    Tags:

  7. Nurses may be a barrier to extended in-center HD treatments

    In a UK study to assess the feasibility of recruiting patients for a trial of 6-hour HD vs. 4-hour, 56 nurses were polled about their attitudes. While 95% of national non-nurse healthcare providers felt that the longer treatments were clinically helpful, just 42% of nurses agreed. And, while 75% of the non-nurses felt that longer HD treatments were well-tolerated, only 45% of nurses thought so—while 83% of nurses were concerned about the impact of the longer treatments on scheduling shifts.

    Read the abstract » | (added 04/10/2015)

    Tags:

  8. Daily HD – fewer hospital days and less dropout than PD

    Compared to PD patients in the USRDS, 1,116 people who did daily home HD had significantly fewer hospital days (5.2 vs. 9.2) and were significantly less likely to switch back to standard in-center treatment (15% vs. 44%). Hospital rates for daily home HD were about the same as those for standard in-center HD in this study.

    Read the abstract » | (added 04/10/2015)

    Tags:

  9. ACTIVE trial of extended dialysis described

    A Clinical Trial of IntensiVE (ACTIVE) Dialysis is a randomized trial of extended (24+ hours) or standard (12-18 hours) of weekly HD for 12 months, looking at quality of life, left ventricular mass, and safety. The study has 200 participants from Australia, China, Canada, and New Zealand, meeting the planned recruitment target. The trial is registered at clinicaltrials.gov (NCT00649298).

    Read the abstract » | (added 04/10/2015)

    Tags:

  10. Biocompatible PD fluid reduces cell death due to inflammation

    In time, the peritoneum (just one cell layer thick) can wear out when used for PD. A new study finds that peritoneal cells in petri dishes bathed in standard PD fluid were more likely to die due to inflammation caused by glucose. But, cells bathed in biocompatible fluids were protected from the damage. In humans, this means that the peritoneum may last longer.

    Read the abstract » | (added 04/10/2015)

    Tags: